

CAU-1804
16346
PATENTATTORNEY DOCKET NO. 07256/024001
UC REFERENCE NO. SD96-043-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: John S. O'Brien
Serial No.: 08/928,074
Filed: 9/11/97
Title: METHODS OF ALLEVIATING NEUROPATHIC PAIN

Art Unit: 1801
Examiner: Not Assigned

Assistant Commissioner for Patents
Washington, DC 20231

RECEIVED

FEB 27 1998

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the attached form PTO 1449, copies of which are enclosed. The following references are not enclosed since they were submitted in the previous Information Disclosure Statement filed, December 22, 1997:

U.S. Patent No. 5,571,787

Bennet, *An Animal Model of Neuropathic Pain: A Review.*, Muscle and Nerve 16:1040-1048, (October 1993)

Campana *et al.*, *Prosaptide, a Peptide Derived from Prosaposin, Induces Motor Endplate Sprouting and Prevents Taxol Neuropathy.*, Society for Neurosciences, 21: 554

Jackowski, *Neural Injury Repair: Hope for the Future as Barriers to Effective CNS Regeneration Become Clearer.* British Journal of Neurosurgery 9: 303-317

Kotani *et al.*, *A Hydrophilic Peptide Comprising 18 Amino Acid Residues of the Prosaposin Sequence has Neurotrophic Activity In Vitro and In Vivo.* Journal of Neurochemistry 66(5): 2197-2200

McMahon *et al.*, *Peripheral Neuropathies and Neurotrophic Factors: Animal Models and Clinical Perspectives.* Current Opinion in Neurobiology 5: 616-624

Date of Deposit

2/19/98

I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Sara Long
for me

Myers, *The Pathogenesis of Neuropathies Pain* Regional Anesthesia. 20(3): 173-184 (May-June 1995)

O'Brien *et al.*, *Identification of the Neurotrophic Factor Sequence of Prosaposin*. The FASEB Journal 9: 681-685 (May 1995)

Sano *et al.*, *Protection by Prosaposin Against Ischemia-Induced Learning Disability and Neuronal Loss*. Biochemical and Biophysical Research Communications 204(2): 994-1000 (Oct 28 1994)

A copy of a communication from a foreign patent office in a counterpart application is also enclosed.

This statement is being filed after a first Office action on the merits, but before receipt of a final Office action or a Notice of Allowance. I, the undersigned, hereby certify that each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application, the communication being dated January 27, 1998, which is not more than three months prior to the filing of this statement. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date:

2/19/98



Lisa A. Haile, Ph.D.
Reg. No. 38,347

Fish & Richardson P.C.
4225 Executive Square, Suite 1400
La Jolla, CA 92037

Telephone: 619/678-5070
Facsimile: 619/678-5099